Epidemiology study of malaria transmission intensity in sub-Saharan Africa
Trial overview
Number of subjects with Plasmodium falciparum (P. falciparum) parasitaemia (PFP), by study center
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects with malaria control interventions (MCIs), overall
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects infected with P.falciparum parasitemia receiving malaria control interventions (MCIs), by infection status
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Odds Ratio (OR) for the number of subjects with MCI, infected with P. falciparum parasitemia, for the Nouna center in Burkina Faso
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Odds Ratio for the number of subjects with MCI, infected with P. falciparum parasitemia, for the Ouagadougu center in Burkina Faso
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Odds Ratio for the number of subjects with MCI, infected with P. falciparum parasitemia, for the Keur Soce center in Dakar area in Senegal
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Odds Ratio for the number of subjects with MCI, infected with P. falciparum parasitemia, for the Niakhar center in Dakar area in Senegal
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects with other medical history characteristics, overall
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects by age, according to P. falciparum infection status
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects by JTEG age group, according to P. falciparum infection status
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects by gender, according to P. falciparum infection status
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects with Plasmodium species other than P. falciparum, by JTEG age group and per total centers
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects with anti-malarial therapy, overall
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of days with therapy, overall
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Days of malaria treatment, overall
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects with fever, overall
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Days with fever, overall
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects with P. falciparum living in the same house, overall
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Descriptive statistics for subjects with P. falciparum living in the same house, overall
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects with different P. Falciparum parasite densities, living in the same house, by center
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Descriptive statistics for subjects with different P. Falciparum parasite densities, living in the same house, by center
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects with P. falciparum by situation area, overall
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects with different P. falciparum densities by situation area and center
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects with P. falciparum by house construction material and other house information, overall
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Number of subjects with different P. falciparum parasite densities, by house information and center
Timeframe: At Epoch 1 (Survey visit) (approximately 35 days)
Participation criteria
- Subjects’ parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- A male or female equal or more than 6 months of age and less than 10 years of age at the time of survey.
- Child in care.
- Current active participation in any trial involving administration of an investigational malaria vaccine or malaria drug.
- A male or female equal or more than 6 months of age and less than 10 years of age at the time of survey.
- Signed informed consent or thumb-printed and witnessed informed consent obtained from the parent(s)/LAR(s) of the child.
Subjects’ parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- Current active participation in any trial involving administration of an investigational malaria vaccine or malaria drug.
Child in care.
Trial location(s)
Study documents
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.